Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 436,319
  • Shares Outstanding, K 169,774
  • Annual Sales, $ 17,460 K
  • Annual Income, $ -149,210 K
  • 60-Month Beta 1.07
  • Price/Sales 3.64
  • Price/Cash Flow N/A
  • Price/Book 3.36
Trade VSTM with:

Options Overview

Details
  • Implied Volatility 144.61%
  • Historical Volatility 77.13%
  • IV Percentile 29%
  • IV Rank 11.53%
  • IV High 598.61% on 09/02/20
  • IV Low 85.45% on 06/22/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 423
  • Volume Avg (30-Day) 2,028
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 18,340
  • Open Int (30-Day) 19,392

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +78.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.87 +32.35%
on 01/27/21
3.04 -18.59%
on 02/17/21
+0.33 (+15.65%)
since 01/25/21
3-Month
1.86 +33.06%
on 11/27/20
3.04 -18.59%
on 02/17/21
+0.77 (+45.59%)
since 11/25/20
52-Week
1.08 +129.17%
on 09/04/20
4.67 -47.00%
on 04/23/20
+0.50 (+25.63%)
since 02/25/20

Most Recent Stories

More News
Thinking about buying stock in PAVmed, Kintara Therapeutics, Seelos Therapeutics, Novan, or Verastem?

KTRA : 2.00 (-9.09%)
NOVN : 1.6400 (-6.82%)
SEEL : 3.17 (-5.09%)
VSTM : 2.42 (-5.84%)
PAVM : 4.73 (+1.07%)
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite's...

VSTM : 2.42 (-5.84%)
GILD : 62.96 (-1.18%)
Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the departure of the Company's...

VSTM : 2.42 (-5.84%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase...

VSTM : 2.42 (-5.84%)
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

--Verastem Recently Initiated Registration-Directed Trials with VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer

VSTM : 2.42 (-5.84%)
Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present...

VSTM : 2.42 (-5.84%)
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

--Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors

VSTM : 2.42 (-5.84%)
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

ALIM : 8.08 (-10.12%)
ABEO : 2.66 (+20.91%)
VSTM : 2.42 (-5.84%)
ASLN : 4.46 (+26.70%)
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

--Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib

VSTM : 2.42 (-5.84%)
Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

--On Track to Commence Company-Sponsored Phase 2 Registration-Directed Trials by Year-End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer

VSTM : 2.42 (-5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 2.99
2nd Resistance Point 2.82
1st Resistance Point 2.70
Last Price 2.42
1st Support Level 2.41
2nd Support Level 2.24
3rd Support Level 2.12

See More

52-Week High 4.67
Fibonacci 61.8% 3.30
Fibonacci 50% 2.87
Fibonacci 38.2% 2.45
Last Price 2.42
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar